Article

Case report: Response with chemotherapy and Olaparib in a patient with advanced cervical adenocarcinoma

2023-03-28

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Cervical adenocarcinomas are a heterogeneous group of tumors, accounting for approximately 20% of all cervical cancers. Many clinical data suggest that the activity of PARPi inhibitors may not be limited to BRCA mutated tumours and may involve the homologous recombination pathway. At present, there are few data available on the activity of PARPi in endometrial a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b3cbefff-e722-5bb3-972c-ee465a3aadd3
DOI: 10.21203/rs.3.rs-2731213/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Case report: Response with chemotherapy and Olaparib in a patient with advanced cervical adenocarcinomaDOI 10.21203/rs.3.rs-2731213/v1Read

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.Semantic proximity Read

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read

PARP Inhibitors in Endometrial Cancer: Current Status and PerspectivesSemantic proximity Read

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read

Major clinical research advances in gynecologic cancer in 2017.Semantic proximity Read

Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial CancerSemantic proximity Read

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read

Untitled literature recordSemantic proximity Read

Poly (ADP-Ribose) polymerase inhibitors have efficacy in a fraction of platinum-resistant ovarian cancer patientsSemantic proximity Read

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experienceSemantic proximity Read

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitorSemantic proximity Read

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.Semantic proximity Read